NEW YORK, July 18, 2011 /PRNewswire/ -- NeoStem, Inc., (NYSE-Amex: NBS) today announced that it intends to offer and sell shares of its common stock and warrants in an underwritten public offering. All of the shares and warrants in the offering will be sold by NeoStem. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The shares will be issued pursuant to a prospectus supplement filed as part of an effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC) on Form S-3.
Lazard Capital Markets, LLC and JMP Securities are acting as joint book-runners of the offering. Morgan Joseph TriArtisan LLC, Maxim Group LLC and National Securities Corporation are acting as co-managers of the offering.
A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and is effective. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020 or via telephone at (800) 542-0970.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. NeoStem intends to file a preliminary prospectus supplement relating to the offering with the SEC, which will be available along with the prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at www.sec.gov.
About NeoStem, Inc.NeoStem, Inc. ("NeoStem") is engaged in the development and manufacturing of cell-based therapies in the U.S. and globally. Its January, 2011 acquisition of Progenitor Cell Therapy ("PCT"), and its July 14, 2011 announcement of the signing of a merger agreement to acquire Amorcyte, Inc. ("Amorcyte"), position NeoStem to achieve its mission of capturing the paradigm shift to cell therapy.
PCT gives NeoStem not only access to a world class contract manufacturing cell therapy company but provides NeoStem a platform and expertise around the evaluation, development and regulatory requirements to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics.
NeoStem also holds the worldwide exclusive license to VSEL(TM) Technology, which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem owns 80% of Athelos Corporation, a company developing a T-cell therapeutic with potential in a range of auto-immune conditions such as graft versus host disease, asthma and diabetes. NeoStem's acquisition of Amorcyte, once the transaction is completed, will give the Company a Phase 2 asset for the treatment of Acute Myocardial Infarctions and a Phase 1 asset for Congestive Heart Failure. NeoStem will own 100% of the worldwide rights to the Amorcyte programs.
Furthermore, NeoStem is building its Chinese presence by establishing an operations lab for cell-based manufacturing in Beijing, as well as commercializing cellular therapies in China through the establishment of relationships with a network of hospitals.
NeoStem also owns a majority-interest in Suzhou Erye Pharmaceutical Company Limited, a world class manufacturing and distribution operation of generic antibiotics in China, with reported revenues of $69 million in 2010.
For more information, please visit: www.neostem.com.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful completion of the public offering described herein. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 6, 2011, its Form 8-K filed on July 14, 2011 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.For more information, please contact:NeoStem, Inc.Robin Smith, CEOPhone: +1-212-584-4174Email: firstname.lastname@example.orgWeb: http://www.neostem.com
SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved
Related medicine technology :
1. NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction
2. NeoStem Announces Agreement with Nankai Hospital in Tianjin to Offer NeoStems Licensed Orthopedic Technology
3. NeoStems Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011
4. NeoStems Subsidiary Progenitor Cell Therapy Receives FACT Accreditation for Its New Allendale, New Jersey Manufacturing Facility
5. NeoStem to Present at 10th Annual Needham Healthcare Conference on Tuesday, April 5
6. NeoStem Provides Results for 2010 and an Update on Recent Activities
7. NeoStem To Present at Rodman & Renshaw Annual China Investment Conference on Tuesday, March 8
8. NeoStem to Launch New Service and Has Engaged Healthcare Personality Dr. Manny Alvarez to Serve as Spokesperson
9. NeoStem to Present at 13th Annual BIO CEO & Investor Conference
10. $1,700,000 Funding of NeoStems Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program
11. NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday, January 12, 2011